State Directory
Provider Records in Massachusetts
GLP1Search tracks 543 provider records across 139 Massachusetts cities. 13 records include explicit GLP-1, medication, or peptide treatment evidence; 530 are directory-only healthcare/provider records that need direct confirmation.
Provider Records
543
Cities
139
Treatment Evidence
13
Directory-Only
530
Market Snapshot
Where source-ready GLP-1 records are concentrated in Massachusetts
The Massachusetts source-ready local index is led by Boston. Across the state, 98% of provider records include phone plus address or website coverage, 8% list public pricing, and 39% carry an upstream source/place signal.
Data Complete
98%
Pricing Visible
8%
Source Flagged
39%
Treatment-Specific Directories
Medication and peptide location pages for Massachusetts
These pages focus on high-intent treatment searches where the state has enough listing density to support a useful directory page.
Top Massachusetts cities for source-ready GLP-1 records
Featured provider records in Massachusetts
Form HealthBoston · $299Semaglutide, TirzepatideGameday Men's Health Boston, MABoston · Contact for PricingSemaglutide evidence, Tirzepatide evidenceDeRosa Center Plastic Surgery and Med SpaBoston · Contact for PricingSemaglutide evidence, Tirzepatide evidenceVIO Med Spa Boston - South EndBoston · Contact for PricingSemaglutide evidence, Tirzepatide evidenceIcon MD Medical Spa + Laser Center BostonBoston · Contact for PricingSemaglutide evidence, Tirzepatide evidence
All covered cities in Massachusetts
Questions about provider records in Massachusetts
How many providers are listed?
GLP1Search lists 543 provider records across 139 cities in Massachusetts, including 13 treatment-evidence records and 530 directory-only records to verify.
Which cities have the most listings?
Boston (140), Newton (16), Brookline (15), Framingham (12), Wellesley (12) currently have the highest listing density in Massachusetts.
What should patients compare?
Compare licensed clinical oversight, medication source, pharmacy type, public pricing, follow-up cadence, side-effect support, and whether the clinic documents semaglutide or tirzepatide availability.